Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Veraxa Biotech (VRXA) AI Stock Analysis

VRXA

Veraxa Biotech

(NASDAQ:VRXA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Veraxa Biotech (VRXA) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%VRXA-89.16%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$161.20M
Dividend Yield
―
Average Volume (3M)
255.66K
Price to Earnings (P/E)
50.8
Beta (1Y)
0.22
Revenue Growth
―
EPS Growth
2.24%
Country
US
Employees
8
Sector
General
Sector Strength
55
Industry
Biotechnology

Veraxa Biotech Business Overview & Revenue Model

Company Description

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary t...

Veraxa Biotech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

VRXA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
INKTINKT55Neutral$53.73M-4.4183.45%――15.65%
INMBINMB49Neutral$40.24M-2.10-82.87%―-100.00%72.25%
XLOXLO44Neutral$52.84M-5.39-50.77%―327.25%85.65%
TCRXTCRX39Underperform$11.83M-0.19-108.72%―2.15%17.34%
PLRXPLRX37Underperform$53.18M-0.58-53.22%――55.84%

* General Sector Average

Performance Comparison

-50%0%50%100%VRXAINMBPLRXTCRXINKTXLODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
VRXA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VRXAVeraxa Biotech Ag1.14-9.35-89.13%
INMBInmune Bio1.45-0.35-19.44%
PLRXPliant Therapeutics, Inc.0.86-0.81-48.62%
TCRXTscan Therapeutics, Inc.0.17-1.07-85.97%
INKTMink Therapeutics, Inc.10.53-2.92-21.71%
XLOXilio Therapeutics Inc8.03-3.87-32.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.